Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver.

Trial Profile

Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Capecitabine (Primary) ; Yttrium-90 (Primary)
  • Indications Cholangiocarcinoma; Liver metastases
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Oct 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 10 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 25 Jun 2013 Planned end date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top